Pipeline


Indication
Product
Research
Discovery
Pre-clinical
PH I
AMD CTx001
AMD CTx003
Complement mediated renal diseases CTx002
Complementome

Treating patients; generating value


  • Pipeline treatments aim to increase the turn-over of C3b
  • Patients' suitability will be determined on the basis of genetic and proteomic background (Complementome)
  • Potential to expand in pre-GA populations (esp. CTx003)
  • Patient ID/Stratification assay being developed

Core Technology Facility
46 Grafton Street
Manchester
M13 9NT
United Kingdom


Created by HTP Digital